Management of Amyotrophic Lateral Sclerosis

European Handbook of Neurological Management: Second Edition

Volumn 1, Issue , 2010, Pages 283-310

  Andersen, P M ^a   Abrahams, S ^b   Borasio, G D ^c   de Carvalho, M ^d   Chio, A ^e   Van Damme, P ^f   Hardiman, O ^g   Kollewe, K ^h   Morrison, K E ⁱ   Petri, S ^h   Pradat, P F ^j   Silani, V ^k   Tomik, B ^l   Wasner, M ^c   Weber, M ^m  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k UNIVERSITY OF MILAN   (Italy)

^l JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^m CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

Amyotrophic lateral sclerosis (ALS) motor neuron disease or MND, characterized by symptoms and signs of degeneration of upper and lower motor neurons; Better patient caregiver satisfaction when effective communication strategies are used; Diagnosing ALS in bulbar and limb regions; Diagnosing ALS, being straightforward patient showing progressive, generalized symptoms in bulbar and limb regions; Diagnostic criteria for ALS; Likelihood of a peaceful death process to be communicated to patients and their caregivers relatives (GPP); Neuromuscular diseases management of amyotrophic lateral sclerosis; Patients with ALS, should be followed in specialist multidisciplinary clinics; Patients with ALS having increased risk of deep venous thrombosis (DVT); Use of complementary and alternative medicine (CAM) frequent in ALS

Indexed keywords

EID: 80053625861     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444328394.ch17     Document Type: Chapter

References (198)

1. Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand 1983; 68: 20-9.
2. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-19.
3. Scott KM, Abhinav K, Stanton BR, et al. Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study. Neuroepidemiology 2009; 32: 81-8.
4. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104-17.
5. Brugman F, Wokke JH, Vianney de Jong JM, Franssen H, Faber CG, Van den Berg LH. Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology 2005; 64: 1778-9.
6. Andersen PM, Borasio GD, Dengler R, et al. EFNS Task Force on Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with Good Practice Points. Eur J Neurol 2005; 12: 921-38.
7. Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur J Neurol 2004; 11: 577-81.
8. Li TM, Day SJ, Alberman E, Swash M. Differential diagnosis of motoneurone disease from other neurological conditions. Lancet 1986; 2: 731-3.
9. Wilbourn AJ. Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. J Neurol Sci 1998; 160 (Suppl. 1): S25-9.
10. Meininger V. Getting the diagnosis right: beyond El Escorial. J Neurol 1999; 246 (Suppl. 3): III10-5.
11. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638-42.
12. Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R, PARALS. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009; 72: 725-31.
13. Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. Neurologist 1999; 5: 63-74.
14. Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002; 73: 199-201.
15. Dengler R, Tröger M. Impact of riluzole on the relationship between patient and physician. J Neurol 2001; 244 (Suppl. 2): S30-2.
16. Lima A, Evangelista T, de Carvalho M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyogr Clin Neurophysiol 2003; 43: 189-92.
17. Evangelista T, Carvalho M, Conceicao I, Pinto A, de Lurdes M, Luis ML. Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1996; 139 (Suppl.): 95-8.
18. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes. Arch Neurol 2000; 57: 109-13.
19. Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J Neurol Sci 1996; 139 (Suppl.): 110-16.
20. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147-51.
21. Brooks BR. Earlier is better: the benefits of early diagnosis. Neurology 1999; 53 (Suppl. 5): S53-4.
22. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
23. Ross MA, Miller RG, Berchert L, et al. Towards earlier diagnosis of ALS. Revised criteria. Neurology 1998; 50: 768-72.
24. Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 110: 497-503.
25. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neuron disease. J Neurol Neurosurg Psychiatry 2003; 70 (Suppl. IV): iv32-47.
26. Lind SE, Good MD, Seidel S, Csordas T, Good BJ. Telling the diagnosis in cancer. J Clin Oncol 1989; 7: 583-9.
27. Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 (Suppl. 1): S127-33.
28. McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 131-5.
29. Damian D, Tattersall MHN. Letters to patients: improving communication in cancer care. Lancet 1991; 338: 923-5.
30. Doyle D. Breaking bad news. J Royal Soc Med 1996; 89: 590-1.
31. Davies E, Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group. Br J Neurosurg 1997; 11: 318-30.
32. Douglass CP, Kandler RH, Shaw PJ, McDermott CJ. An evaluation of neurophysiological criteria used in the diagnosis of Motor Neurone Disease. J Neurol, Neurosurg Psychiatry, in press, 2010.
33. Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V, for the European ALS Study Group. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001a; 2: 159-64.
34. Ackerman GM, Oliver D. Psychosocial support in an outpatient clinic. Palliat Med 1997; 11: 167-8.
35. Howard RS, Orrell RW. Management of motor neurone disease. Postgrad Med J 2002; 78: 736-41.
36. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77: 948-50.
37. Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect of referral bias on assessing survival in ALS. Neurology 2007; 68: 600-2.
38. Traynor BJ, Alexander M, Corr B, et al. Effects of a multidisciplinary ALS clinic on survival. J Neurol Neurosurg Psychiatry 2003a; 74: 1258-61.
39. Zoccolella S, Beghi E, Palagano G, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol 2007; 254: 1107-12.
40. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65: 1264-7.
41. Mayadev AS, Weiss MD, Distad BJ, Krivickas LS, Carter GT. The amyotrophic lateral sclerosis center: a model of multidiciplinary management. Phys Med Rehabil Clin N Am 2008; 19: 619-31.
42. Kareus SA, Kagebein S, Rudnicki SA. The importance of a respiratory therapist in the ALS clinic. Amyotroph Lateral Scler 2008; 9: 173-6.
43. Corr B, Frost E, Traynor BJ, Hardiman O. Service provision for patients with ALS/MND: a cost-effective multidiciplinary approach. J Neurol Sci 2008; 160 (Suppl. 1): S141-5.
44. Chiò A, Gauthier A, Vignola A, et al. Caregiver time use in ALS. Neurology 2006; 67: 902-4.
45. Hecht MJ, Graesel E, Tigges S, et al. Burden of care in amyotrophic lateral sclerosis. Palliat Med 2003; 17: 327-33.
46. Gauthier A, Vignola A, Calvo A, et al. A longitudinal study on quality of life and depression in ALS patient-caregiver couples. Neurology 2007; 68: 923-6.
47. Gelinas DF, O'Connor P, Miller RG. Quality of life for ventilator-dependent ALS patients and their caregivers. J Neurol Sci 1998; 160 (Suppl. 1): S134-6.
48. Kaub-Wittemer D, Steinbüchel N, Wasner M, Laier-Groeneveld G, Borasio GD. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Symptom Manage 2003; 26: 890-6.
49. Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006; 66: 1211-17.
50. Wasner M, Bold U, Vollmer TC, Borasio GD. Sexuality in patients with amyotrophic lateral sclerosis and their partners. J Neurol 2004; 251: 445-8.
51. Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612-16.
52. Hebert RS, Lacomis D, Easter C, Frick V, Shear MK. Grief support for informal caregivers of patients with ALS: a national survey. Neurology 2005; 64: 137-8.
53. Paz-Rodriguez F, Andrade-Palos P, Llanos-Del Pilar AM. Emotional consequences of providing care to amyotrophic lateral sclerosis patients. Rev Neurol 2005; 40: 459-64.
54. Martin J, Turnbull J. Lasting impact in families after death from ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 181-7.
55. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/ Riluzole Study Group. N Engl J Med 1994; 330: 585-91.
56. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-31.
57. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;(2): CD001447.
58. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with ALS treated with riluzole. Arch Neurol 1998; 55: 526-8.
59. Brooks BR, Belden DS, Roelke K, et al. Survival in non-riluzole treated ALS patients is identical before and since 1996: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 (Suppl. 2): 60-1. (Abstract #P15).
60. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15-21.
61. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000. J Neurol 2003b; 250: 473-9.
62. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the gene encoding CuZn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 2: 62-73.
63. Forshew DA, Bromberg MB. A survey of clinicans'practice in the symptomatic treatment of ALS. Amyotrophic Lateral Scler Other Motor Neuron Disord 2003; 4: 258-63.
64. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154: 1214-18.
65. Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary fiow in amyotrophic lateral sclerosis with scopoderm TTS. Head Neck 1989; 11: 565.
66. Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary fiow with transdermal scopolamine: a four-year experience. Otolaryngol Head Neck Surg 1990; 103: 615-18.
67. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-3.
68. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61: 1279-81.
69. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137-43.
70. Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417-18.
71. Andersen PM, Gr önberg H, Funegård U, Franzen L. X-ray radiation of the parotid glands significantly reduces drooling in patients with progressive bulbar palsy. J Neurol Sci 2001; 191: 111-14.
72. Harriman M, Morrison M, Hay J, et al. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001; 30: 242-5.
73. Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58: 1308.
74. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol 2007; 14: 1373-7.
75. Burton MJ. The surgical management of drooling. Dev Med Child Neurol 1991; 33: 1110-6.
76. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician 2004; 69: 2628-34.
77. Janzen VD, Rae RE, Hudson AJ. Otolaryngologic manifestations of ALS. J Otolaryngol 1988; 17: 41-2.
78. Peysson S, Vandenberghe N, Phillit F, et al. Factors predicting survival following noninvasive ventilation in amyotrophic lateral sclerosis. Eur Neurol 2008; 59: 164-71.
79. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 (Suppl.): 43-4.
80. Frass M, Dielacher C, Linkesch M, et al. Infiuence of potassium dichromate on tracheal secretions in critically ill patients. Chest 2005; 127: 936-41.
81. Hanayama K, Ishikawa Y, Bach JR. Amyotrophic lateral sclerosis: successful treatment of of mucous plugging by mechanical insuffiation-exsuffiation. Am J Phys Med Rehabil 1997; 76: 338-9.
82. Sancho J, Servera E, Diaz J, Marin J. Efficacy of mechanical insuffiation-exsuffiation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125: 1400-5.
83. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989; 80: 114-17.
84. Palmieri A, Abrahams S, Sorarù G, et al. Emotional lability in MND: relationship to cognition and psychopathology and impact on caregiver. J Neurol Sci 2009; 278: 16-20.
85. Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbart affect. Drugs Today 2008; 44: 661-8.
86. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. N Engl J Med 1985; 312: 1480-2.
87. Andersen G, Vestergaard K, Riis JO. Citalopram for poststroke pathological crying. Lancet 1993; 342: 837-9.
88. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/ quinidine: a randomized trial. The AVP-923 ALS Study Group. Neurology 2004; 63: 1364-70.
89. Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E. Arch Intern Med 1992; 152: 1877-80.
90. Diener HC, Dethlefsen U, Dethlefsen-Gruber S, Verbeek P. Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. Int J Clin Pract 2002; 56: 243-6.
91. Drory VW, Goltsman E, Renik JG, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133-7.
92. Kesiktas N, Paker N, Erdogan N, Gulsen G, Bicki D, Yilmaz H. The use of hydrotherapy for the management of spasticity. Neurorehabil Neural Repair 2004; 18: 268-73.
93. dos Santos MT, de Oliveira LM. Use of cryotherapy to enhance mouth opening in patients with cerebral palsy. Spec Care Dentist 2004; 24: 232-4.
94. Marquardt G, Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 275-6.
95. McClelland S 3 rd, Bethoux FA, Boulis NM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008; 37: 396-8.
96. Winterholler MG, Heckmann JG, Hecht M, Erbguth FJ. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology 2002; 58: 502-3.
97. Vignola A, Guzzo A, Calvo A, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol 2008; 15: 1231-6.
98. Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol 2007; 14: 993-1001.
99. Mandler RN, Anderson FA Jr, Miller RG, et al. The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotrophic Lateral Scler Other Motor Neuron Disord 2001; 2: 203-8.
100. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology 2002; 59: 428-31.
101. Lou JS. Fatigue in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008; 19: 533-43.
102. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005; 22: 55-9.
103. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 2009; 39: 297-303.
104. Oliver D, Borasio GD, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis, 2nd edn. Oxford: Oxford University Press, 2006.
105. Brettscheneider J, Kurent J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2008; 3: CD005226.
106. Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 246-9.
107. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidense of deep venous thrombosis in ALS. Neurology 2007; 68: 76-7.
108. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 151-4.
109. Vardeny O, Bromberg MB. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). J Herb Pharmacother 2005; 5: 23-31.
110. Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res 2001; 10: 913-15.
111. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008; 265: 78-83.
112. Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008; 71: 1326-34.
113. Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009; 11: 18-25.
114. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009; 11: 26-34.
115. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 2004; 364: 200-2.
116. Badayan I, Cudkowicz ME. Is it too soon for mesenchymal stem cell trials in people with ALS? Amyotroph Lateral Scler 2009; 10: 123-4.
117. Huang H, Chen L, Xi H, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant 2008; 22: 710-18.
118. Huang H, Chen L, Xi H, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2009; 23: 14-20.
119. Chen L, Huang H, Zhang J, et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2007; 21: 961-6.
120. Stober T, Schimrigk K, Dietzsch S, Thielen T. Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. J Neurol 1985; 232: 13-14.
121. Mora JS, Munsat TL, Kao KP, et al. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 1986; 36: 1137-40.
122. Cudkowicz ME, Warren L, Francis JW, et al. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology 1997; 49: 213-22.
123. Aebischer P, Schluep M, Déglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2: 696-9.
124. Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997; 40: 94-9.
125. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-6.
126. Nagano I, Shiote M, Murakami T, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 2005; 27: 768-72.
127. Finsterer J, Mamoli B. Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis. Spinal Cord 1999; 37: 592-3.
128. Finsterer J, Mamoli B. Cerebrospinal fuid filtration in amyotrophic lateral sclerosis. Eur J Neurol 1999; 6: 597-600.
129. Steele J, Matos LA, Lopez EA, et al. A phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 250-4.
130. Zanette G, Forgione A, Manganotti P, Fiaschi A, Tamburin S. The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis. J Neurol Sci 2008; 270: 18-22.
131. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler 2008; 9: 108-19.
132. Haberlandt WF. Genetic aspects of amyotrphic lateral sclerosis and progressive bulbar paralysis. Acta Genet Med Gemell 1959; 8: 369-73.
133. Murros K, Fogelholm R. Amyotrophic lateral sclerosis in middle-Finland: an epidemiological study. Acta Neurol Scand 1983; 67: 41-7.
134. Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg 2000; 100: 84-90.
135. Murray TJ, Pride S, Haley G. Motor neuron disease in Nova Scotia. CMAJ 1974; 110: 814-17.
136. Gunnarsson L-G, Palm R. Motor neuron disease and heavy labour: an epidemiological survey of Värmland county, Sweden. Neuroepidemiology 1984; 3: 195-206.
137. Li T-M, Alberman E, Swash M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1988; 51: 778-84.
138. Giagheddu M, Puggioni G, Masala C, et al. Epidemiologic study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol Scand 1983; 68: 394-404.
139. Højer-Pedersen E, Christensen PB, Jensen NB. Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology 1989; 8: 151-9.
140. Fong KY, Yu YL, Chan YW, et al. Motor neuron disease in Hong Kong Chinese: epidemiology and clinical picture. Neuroepidemiology 1996; 15: 239-45.
141. Jokelainen M. Amyotrophic lateral sclerosis in Finland. II: clinical characteristics. Acta Neurol Scand 1977; 56: 194-204.
142. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset ALS associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119: 1153-72.
143. Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995; 32: 290-2.
144. Gil J, Funalot B, Verschueren A. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol 2008; 15: 1245-51.
145. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000-13.
146. Pinto A, de Carvalho M, Evangelista T, Lopes A, Sales-Luis L. Nocturnal pulse oxymetry: a new approach to establish the appropriate time for non-invasive ventilation. Amyotroph Lateral Scler 2003; 4: 31-5.
147. Pinto S, Turkman A, Pinto A, Swash M, de Carvalho M. Predicting respiratory insufficiency in amyotrophic lateral sclerosis: the role of phrenic nerve studies. Clin Neurophysiol 2009; 120: 941-6.
148. Sancho J, Servera E, Dias J, Marin J. Prediction of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2007; 175: 1266-71.
149. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 67-71.
150. Mendoza M, Gelinas DF, Moore DH, Miller RG. A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in ALS. Amyotroph Lateral Scler 2007; 8: 106-11.
151. Pinto A, Evangelista T, de Carvalho M, Alves MA, Sales-Luis ML. Respiratory assistance with a non-invasive ventilator (BiPAP) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129 (Suppl.): 19-26.
152. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5: 140-7.
153. Lo Cocco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Cocco A. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation. Chest 2007; 132: 64-9.
154. Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball R, Wiener CM. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotr Lat Scler 2007; 8: 185-8.
155. Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 2007; 78: 629-31.
156. Onders RP, Carlin AM, Elmo M, Sivashankaran S, Katirii B, Schilz R. Amyotrophic lateral sclerosis: the Midwestern surgical experience with diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg 2009; 197: 386-90.
157. Nardin R, O'Donnell C, Loring SH, et al. Diaphragm training in amyotrophic lateral sclerosis. J Clin Neuromusc Dis 2008; 10: 56-60.
158. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996; 139 (Suppl.): 123-8.
159. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-44.
160. Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17: 659-63.
161. Winck JC, Gonçalves MR, Lourenço C, Viana P, Almeida J, Bach JR. Effects of mechanical insuffiation-exsuffiation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest 2004; 126: 774-80.
162. Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology 2006; 67: 991-7.
163. Desport JC, Marin B, Funalot B, Preux PM, Curatirer P. Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9: 273-8.
164. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005; 2: 202-7.
165. Vaisman N, Lusaus M, Nefussy B, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 2009; 279: 26-9.
166. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91-6.
167. Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 72-83.
168. Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006; 7: 16-21.
169. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40: 463-9.
170. Chio A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004; 75: 645-7.
171. Shaw AS, Ampong MA, Rio A, McClure J, Leigh PN, Sidhu PS. Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology 2004; 233: 392-9.
172. Thornton FJ, Fotheringham T, Alexander M, Hardiman O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: enteral nutrition provision-endoscopic or radiologic gastrostomy? Radiology 2002; 224: 713-17.
173. Scott AG, Austin HE. Nasogastric feeding in the management of severe dysphagia in motor neurone disease. Palliat Med 1994; 8: 45-9.
174. Verschueren A, Monnier A, Attarian S, Lardillier D, Pouget J. Enteral and parenteral nutrition in the later stages of ALS: an observational study. Amyotroph Lateral Scler 2009; 10: 42-6.
175. Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005; 65: 1774-7.
176. Phukan J, Pender N, Hardiman O. Cognitive impairment in ALS. Lancet Neurol 2007; 6: 994-1003.
177. Neary D, Snowden JS, Mann DM. Classification and description of frontotemporal dementias. Ann N Y Acad Sci 2000; 920: 46-51.
178. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60: 1094-7.
179. Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 3-131.
180. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology 2005; 64: 1222-6.
181. Grossman AB, Woolley-Levine S, Bradley WG, Miller RG. Detecting neurobehavioral changes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8: 56-61.
182. Gibbons ZC, Richardson A, Neary D, Snowden JS. Behaviour in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9: 67-74.
183. Papps B, Abrahams S, Wicks P, Leigh PN, Goldstein LH. Changes in memory for emotional material in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2005; 43: 1107-14.
184. Gibbons ZC, Snowden JS, Thompson JC, Happe F, Richardson A, Neary D. Inferring thought and action in motor neurone disease. Neuropsychologia 2007; 45: 1196-207.
185. Abrahams S, Goldstein LH, Suckling J, et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol 2005; 252: 321-31.
186. Murphy JM, Henry RG, Langmore S, Kramer JH, Miller BL, Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007; 64: 53053-4.
187. Donaghy C, Pinnock R, Abrahams S. Ocular fixation instabilities in motor neurone disease. A marker of frontal lobe dysfunction? J Neurol 2009; 256: 420-6.
188. Flaherty-Craig C, Eslinger P, Stephens B, Simmons Z. A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology 2006; 67: 2070-2.
189. Gordon PH, Wang Y, Doorish C, et al. A screening assessment of cognitive impairment in patients with ALS. Amyotroph Lateral Scler 2007; 8: 362-5.
190. Grossman M, Anderson C, Khan A, et al. Impaired action knowledge in amyotrophic lateral sclerosis. Neurology 2008; 71: 1396-401.
191. Raaphorst J, De Visser M, Linssen WH, et al. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler 2010; 11: 27-37.
192. Bak TH, Hodges JR. Motor neurone disease, dementia and aphasia. Coincidence, co-occurrence or continuum. J Neurol 2001; 248: 260-70.
193. Cobble M. Language impairment in motor neurone disease. J Neurol Sci 1998; 160 (Suppl. 1): S47-52.
194. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001; 19: 829-47.
195. Mitsumoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 145-54.
196. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 1998; 339: 967-73.
197. Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, van den Berg LH. Euthanasia and physicianassisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002; 346: 1638-44.
198. Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 2003; 163: 341-4.